+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses



Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular Disease: Randomized and Observational Comparisons of Secondary Prevention Trials and Their Meta-analyses



Perspectives in Vascular Surgery and Endovascular Therapy 17(1): 65-1-67




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 063338454

Download citation: RISBibTeXText

DOI: 10.1177/153100350501700115


Related references

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Archives of Internal Medicine 164(1): 40-44, 2004

An Update on Current Management Strategies for Achalasia and Future Perspectives. Journal of Clinical Gastroenterology, 2017

Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease Randomized and observational comparisons of secondary prevention trials and their meta-analysis. Journal of the American College of Cardiology 41(6 Supplement A): 526A, March 19, 2003

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. American Heart Journal 162(1): 115-24.E2, 2011

Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. Journal of Internal Medicine 257(5): 399-414, 2005

Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. American Journal of Medicine 125(2): E13-E13, 2012

Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA 301(18): 1909-1919, 2009

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovascular Diabetology 16(1): 134-134, 2017

The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. Journal of the Neurological Sciences 332(1-2): 92-96, 2014

Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Archives of Internal Medicine 162(19): 2197-2202, 2002

Prevention of cardiovascular disease: risks and benefits of aspirin. Journal of General Internal Medicine 5(5 Suppl): S54-S57, 1990

Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. Journal of Thoracic and Cardiovascular Surgery 143(3): 665-675.E4, 2012

Meta analyses of trials of aspirin in cardiovascular disease. Leaf, A And P C Weber (Ed ) Atherosclerosis Reviews, Vol 21 Prevention And Noninvasive Therapy Of Atherosclerosis; International Workshop, Key West, Florida, Usa, November 30-December 2, 1989 Xiii+206p Raven Press: New York, New York, Usa Illus 145-150, 1990

Effect of tea on blood pressure for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews 73(4): 236-246, 2015

Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. Italian Heart Journal 4(4): 228-231, 2003